Te
Associate Medical Director - Migraine EU
Teva Pharmaceuticals
Full-time
Haarlem, Netherlands
other-general
Posted:
March 03, 2026
Location:
Haarlem, Netherlands, Netherlands
Job Description
Associate Medical Director - Migraine EU
Date: Feb 21, 2026
Location:
Haarlem, Netherlands, 2031GA
Company: Teva Pharmaceuticals
Job Id: 65108
**We Are Teva**
We’re Teva, a leading innovative biopharmaceutical company, enabled by a world-class generics business. Whether it’s innovating in the fields of neuroscience and immunology or delivering high-quality medicine worldwide, we’re dedicated to addressing patients’ needs now and in the future. Here, you will be part of a high-performing, inclusive culture that values fresh thinking and collaboration. You'll have the room to grow, the flexibility to balance life with work, and the opportunity to better health worldwide, together.
**Location**
This role will be based in our European HQ in Haarlem
You will be traveling mainly to other EU locations. The expected ...
Date: Feb 21, 2026
Location:
Haarlem, Netherlands, 2031GA
Company: Teva Pharmaceuticals
Job Id: 65108
**We Are Teva**
We’re Teva, a leading innovative biopharmaceutical company, enabled by a world-class generics business. Whether it’s innovating in the fields of neuroscience and immunology or delivering high-quality medicine worldwide, we’re dedicated to addressing patients’ needs now and in the future. Here, you will be part of a high-performing, inclusive culture that values fresh thinking and collaboration. You'll have the room to grow, the flexibility to balance life with work, and the opportunity to better health worldwide, together.
**Location**
This role will be based in our European HQ in Haarlem
You will be traveling mainly to other EU locations. The expected ...
Apply for this Job
Submit your application for the Associate Medical Director - Migraine EU position at Teva Pharmaceuticals.
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Haarlem, Netherlands
Posted:
March 03, 2026
Deadline:
April 05, 2026